Drugs & Therapy Perspectives

, Volume 8, Issue 10, pp 1–6 | Cite as

HIV protease inhibitors: an important advance

New Drugs and Therapeutic
  • 4 Downloads

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Saquinavir mesylate monograph. AHFS Drug Information 96. Current developments. Bethesda: American Society of Hospital Pharmacists, 1996: 47–54Google Scholar
  2. 2.
    Moyle G, Gazzard B. Current knowledge and future prospects for the use of HIV protease inhibitors. Drugs 1996 May; 51(5): 701–12PubMedCrossRefGoogle Scholar
  3. 3.
    Indinavir sulfate. AHFS Drug Information 96. Current developments. Bethesda: American Society of Hospital Pharmacists, 1996: 24–28Google Scholar
  4. 4.
    Lea AP, Faulds D. Ritonavir. Drugs 1996 Oct; 52(4): 541–9PubMedCrossRefGoogle Scholar
  5. 5.
    Noble S, Faulds D. Saquinavir: a review of its pharmacology and clinical potential in the management of HIV infection. Drugs 1996 Jul; 52(1): 93–112PubMedCrossRefGoogle Scholar
  6. 6.
    New drugs for HIV infection. Med Lett 1996 Apr 12; 38(972): 35–7Google Scholar
  7. 7.
    Merck Crixivan temporary distribution to begin filling scripts March 25 through independent pharmacy service; scale-up facilities to be ready in six months. The Pink Sheet, FDC Reports 1996 Mar 18: 4Google Scholar
  8. 8.
    Swift US approval for Abbott’s Norvir. Scrip 1996 Mar 8; (2109): 17Google Scholar
  9. 9.
    Carpenter CJ, Fischl MA, Hammer SM, et al. Antiretroviral therapy for HIV infection in 1996: Recommendations of an international panel. JAMA 1996 Jul 10; 276(2): 146–56PubMedCrossRefGoogle Scholar
  10. 10.
    Merck’s Crixivan recommended for US approval. Scrip 1996 Mar 8; (2109): 18Google Scholar
  11. 11.
    Vella S, Galluzzo C, Giannini G, et al. Saquinavir/zidovudine combination in patients with advanced HIV infection and no prior antiretroviral therapy: CD4+ lymphocyte/plasma RNA changes, and emergence of HIV strains with reduced phenotypic sensitivity. Antiviral Res 1996; 29: 91–3PubMedCrossRefGoogle Scholar
  12. 12.
    Cameron DW, Heath-Chiozzi M, Kravcik S, et al. Prolongation of life and prevention of AIDS complications in advanced HIV immunodeficiency with ritonavir; update [abstract]. XI International Conference on AIDS; 1996 Jul 7; VancouverGoogle Scholar
  13. 13.
    Collier AC, Coombs RW, Schoenfeld DA, et al. Treatment of human immunodeficiency virus infection with saquinavir, zidovudine, and zalcitabine. N Engl J Med 1996; 334: 1011–7PubMedCrossRefGoogle Scholar
  14. 14.
    Bleeding warnings for protease inhibitors. Scrip 1996 Jul 26; (2149): 17Google Scholar
  15. 15.
    Norvir capsules and solution. Pharm J 1996 Sep 7; 257: 330Google Scholar
  16. 16.
    New data on protease inhibitors from Vancouver. Scrip 1996 Jul 23; (2148): 17Google Scholar
  17. 17.
    Schapiro JM, Winters MA, Kozal MJ, et al. Saquinavir monotherapy trial: prolonged suppression of viral load and resistance mutations with higher dosage [abstract no. LB-5]. 35th Interscience Conference on Antimicrobial Agents and Chemotherapy; 1995 Sep 17–20; San Francisco, 8Google Scholar
  18. 18.
    Lamivudine and stavudine: useful additions to the available nucleoside analogues. Drug Ther Perspect 1996 Oct 14; 8(8): 1–6CrossRefGoogle Scholar
  19. 19.
    Moore RD, Bartlett JG. Combination antiretroviral therapy in HIV infection: an economic perspective. PharmacoEconomics 1996 Aug;10(2): 109–13PubMedCrossRefGoogle Scholar

Copyright information

© Adis International Limited 1996

Personalised recommendations